CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy
Blood and Genomics · 30.06.2026 · 10 (1) · 1-8
DOI: 10.46701/bg.20260101002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood and Genomics, online erschienen am 30.06.2026. Verfasst von Yu Jin und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Red blood cell (RBC) disorders, including sickle cell anemia and β-thalassemia, are emerging as a significant global public health concern. Clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9)-mediated genome editing technology, commonly referred to as CRISPR/Cas9, is a precise and efficient genome-editing tool that has demonstrated considerable potential in advancing research on erythroid diseases. This review elucidates the molecular mechanisms underlying CRISPR/Cas9 technology and systematically illustrates its applications in generating animal models for RBC disorders, investigating erythrocyte differentiation pathways, and developing novel therapeutic strategies. Furthermore, the review critically evaluated the current challenges and future directions for CRISPR/Cas9-based approaches, providing insights to guide both fundamental research and clinical translation in the context of these hematologic conditions.
Zitieren
APA
Jin, Y., Zhang, Y., Ling, Y., Fu, Q., & He, C. (2026). CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy. Blood and Genomics, 10(1), 1-8. https://doi.org/10.46701/bg.20260101002
Vancouver
Jin Y, Zhang Y, Ling Y, Fu Q, He C. CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy. Blood and Genomics. 2026;10(1):1-8. doi:10.46701/bg.20260101002
BibTeX
@article{Jin2026,
author = {Jin, Yu and Zhang, Yu and Ling, Yating and Fu, Qiang and He, Chengtao},
title = {CRISPR/Cas9 in red blood cell-related diseases: breakthroughs in gene editing and therapy},
journal = {Blood and Genomics},
year = {2026},
volume = {10},
number = {1},
pages = {1--8},
doi = {10.46701/bg.20260101002}
}
EUVIMED